Bookmark

Add to MyYahoo RSS

Gilead Sciences News

News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.

Friday Aug 29 | Seeking Alpha

Today's Market: Red Hot Biotech And Big Pharma Names To Watch

A busy week is about to come to an end, but not before we have learned a lot about the strength of this market and just how resilient it is.

Comment?

Related Topix: Biotech, Science / Technology, Medicine, Amgen, Healthcare Industry, Startups, Gilead Sciences, CGI Pharmaceuticals

Friday Aug 29 | BioSpace

Gilead Sciences, Inc., "The New Genentech," Remaps Massive Foster City Campus

Gilead Sciences Inc. is the new Genentech, with a long-range plan for higher-density growth that literally cements its standing as one of the world's largest biotech drug developers.

Comment?

Related Topix: Biotech, Gilead Sciences, Medicine, Healthcare Industry, Startups

Thu Aug 28, 2014

Seeking Alpha

When Will M&A Come To The Hepatitis C Space?

Biotech InterMune was taken out by Roche for over $8 billion yesterday in a deal that had an almost 40% buyout premium.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, InterMune, Healthcare Industry, Gilead Sciences, Startups, CGI Pharmaceuticals, Achillion Pharmaceuticals

Wed Aug 27, 2014

Seeking Alpha

Gilead Sciences: Due For More Short Squeezing?

Short sellers of Gilead Sciences must be starting to sweat a bit as the stock continues its impressive trajectory: However, the short interest figures just came out for the first half of August and they in fact show that about 8 million shares were covered in that time period.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals

Tue Aug 26, 2014

Barron's

Biotech Stocks: Time to Worry

I mean, just look at these returns: Gilead Sciences has gained 41% so far this year as investors appear to have put their Sovaldi worries behind them ; InterMune has quintupled in 2014 after Roche agreed to purchase it for $8.3 billion ; and Intercept Pharmaceuticals has surged 350% as drug trials have been surprisingly good .

Comment?

Related Topix: Biotech, Science / Technology, Financial Markets, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, InterMune

Mon Aug 25, 2014

Investopedia

4 Large-Cap Healthcare Stocks To Watch

Healthcare has been one of the hottest sectors over the last year and continues to find new highs.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups

SchaeffersResearch.com

Gilead Sciences, Inc. (GILD) Trader Sets a Short-Term Top

At last check, the shares were still 2.7% higher at $106.72. Not surprisingly, calls are the options of choice, with volume running at three times the usual intraday pace.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Day Trading, Financial Markets, Personal Finance

Reuters

Us Stocks-S&P 500 tops 2,000 for first time in broad advance

The S&P 500 stock index rose to an intraday record on Monday, topping 2,000 for the first time in a broad rally led by financial and biotechnology stocks.

Comment?

Related Topix: Financial Markets, Biotech, Science / Technology, InterMune, Medicine, Healthcare Industry, Startups, CGI Pharmaceuticals, Annapolis, MD

Sat Aug 23, 2014

AmericanBankingNews.com

RBC Capital Increases Gilead Sciences Price Target to $115.00

The firm currently has an "outperform" rating on the stock. RBC Capital's price target points to a potential upside of 10.62% from the company's current price.

Comment?

Related Topix: Biotech, Startups, Medicine, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry

Thu Aug 21, 2014

TheStreet.com

Jim Cramer's Stop Trading: Don't Worry About Gilead Sciences

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Mozilla, TheStreetcom, Media, TheStreet, Computers

Wed Aug 20, 2014

AmericanBankingNews.com

Recent Analysts' Ratings Updates for Gilead Sciences

A number of stock research firms have changed their ratings and price targets for Gilead Sciences during the last seven days: Gilead Sciences is now covered by analysts at Argus.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals

Foster's Daily Democrat

$1,000 Sovaldi now hepatitis treatment of choice

The price is sky-high, but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Gilead Sciences, Healthcare Industry, Startups, Health Insurance, Medicaid

Mon Aug 18, 2014

Investopedia

4 Large-Cap Healthcare Stocks To Watch

Healthcare has been one of the hottest sectors over the last year and continues to find new highs.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups

Sat Aug 16, 2014

Knoxville News Sentinel

David Moon: Breakthrough pill presents puzzle The U.S. Centers for...

The U.S. Centers for Disease Control and Prevention estimates there are 3.2 million Americans with chronic hepatitis C, 17,000 of whom will die this year as a result of the infection - a number that exceeds the annual deaths from HIV/AIDS in the U.S. Fortunately, Gilead Sciences produces a new breakthrough drug, Sovaldi, which has proved to cure 90 ... (more)

Comment?

Related Topix: Centers for Disease Control and Prevention, Gilead Sciences, Biotech, Medicine, Healthcare Industry, Startups, US News, US Senate, Ron Wyden, Democrat, US Politics, Republican, Chuck Grassley, Sports

PR-inside.com

New Market Research Report: Pharmasset, Inc - Pharmaceuticals &...

The company is engaged in discovering, producing and commercializing medicines to treat viral infections.

Comment?

Related Topix: Pharmaceuticals, Pharmasset, Hepatitis, Medicine, Health, Biotech, Gilead Sciences, Healthcare Industry, Startups

Fri Aug 15, 2014

Seeking Alpha

Gilead: Rising Short Interest Provides Yet Another Reason To Own The Stock

Its forward P/E is low relative to the market, thus incorporating caution about the sustainability of profits from its hepatitis C franchise.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Pharmaceuticals, Pharmasset

SchaeffersResearch.com

Analyst Update: J C Penney Company Inc, Monster Beverage Corp, and Gilead Sciences, Inc.

However, J.P. Morgan Securities raised its price target on JCP to $11 from $9, representing an unusually bullish forecast for the stock.

Comment?

Related Topix: JC Penney, Biotech, Retail, Medicine, Gilead Sciences, Healthcare Industry, Monster Worldwide, Startups, Human Resources, Advertising, Day Trading, Financial Markets, Personal Finance

Business Journal

Gilead beats back Roche, wins U.K. victory for hepatitis C drug Sovaldi

An arbitration panel ruled Friday that the Foster City-based drug maker's hepatitis C blockbuster Sovaldi did not infringe a 2004 research deal that rival Roche had with Pharmasset Inc. Gilead , led by Chairman and CEO John Martin , bought Pharmasset in 2012 for $11 billion, landing the drug that would become Sovaldi.

Comment?

Related Topix: Startups, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Pharmaceuticals, Pharmasset, Genentech

Seeking Alpha

Gilead: More Good News For This Biotech Juggernaut

Highlighted below is my rebuttal to a recent short thesis on Gilead and why is stock is still cheap and going much higher.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals

BioSpace

Gilead Sciences, Inc. Shaky As Achillion Pharmaceuticals, Inc.'s...

Achillion Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naA ve genotype 1 chronic hepatitis C virus infection.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Achillion Pharmaceuticals, Pharmaceuticals

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••